An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

On Friday, Novo Nordisk released promising trial results for its obesity treatment, amycretin, which showed a significant weight loss in participants, outpacing Eli Lilly's own drug in early ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... He acknowledged challenges with the drug’s launch but remains optimistic about its long-term prospects.

Hopes were high for a rebound in capital-markets activity this year A few notable Health Care deals along with M&A in the ...

Investing.com -- Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from competitor Novo Nordisk (NYSE:NVO) regarding their new ...

In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money.

The GLP-1 drug ... Eli Lilly's market share over time. For example, Amgen (AMGN) is developing MariTide and Pfizer (PFE) is developing oral GLP-1 candidates. Again, the similarity to Nvidia in AI ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

All of the world’s top 10 biggest drug makers by market cap have invested in AI through in-house development and startup partnerships. Among them is Eli Lilly from the U.S., which inked a deal ...

Eli Lilly and venture ... Catalyze360 leverages Lilly Ventures, Lilly Gateway Labs and Lilly ExploR&D to create a multi-armed resource for early-stage drug developers. The company’s Gateway ...